Showing results (1361-1370 of 6,507) with videos related to

Sort By:
Pageof 651
Cancer Immunology, Immunotherapy : CII|August 5, 2022
Low-dose anlotinib confers improved survival in combination with immune checkpoint inhibitor in advanced non-small cell lung cancer patientsShumin Yuan, Ling Peng, Yuqing Liu, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1987
Oncostatic and immunomodulatory effects of a glycoprotein fraction from water extract of abalone, Haliotis discus hannaiH Uchida, T Sasaki, N A Uchida, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1987
High-dose, unlabeled, nonspecific antibody pretreatment: influence on specific antibody localization to human melanoma xenograftsR L Wahl, B S Wilson, M Liebert, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1987
Depression of cell-mediated immunity by tumour cell products: induction of resistance by immunotherapeutically active extracts of bovine ocular squamous cell carcinomaM Nelson, D S Nelson, V K Kuchroo, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1987
Expression of HLA-DR antigens on tumour cells does not contribute to skin reactivity to autologous cholesteryl hemisuccinate (CHS)-treated tumour cells in patients with metastatic melanomaM Munzarová, D Zemanová, J Kovarík, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1987
Synergistic antitumor activity of cyclophosphamide and ABPP in the treatment of established and advanced tumors in murine tumor modelsA M Eggermont, P H Sugarbaker, R L Marquet, et al.
Cancer Immunology, Immunotherapy : CII|November 11, 2022
Novel ocular immunotherapy induces tumor regression in an equine model of ocular surface squamous neoplasiaKathryn L Wotman, Lyndah Chow, Brittany Martabano, et al.
Cancer Immunology, Immunotherapy : CII|February 24, 2023
Associations between KIR/KIR-ligand genotypes and clinical outcome for patients with advanced solid tumors receiving BEMPEG plus nivolumab combination therapy in the PIVOT-02 trialA S Feils, A K Erbe, J Birstler, et al.
Cancer Immunology, Immunotherapy : CII|March 17, 2023
Tumour microenvironment as a predictive factor for immunotherapy in non-muscle-invasive bladder cancerAleksandra Semeniuk-Wojtaś, Karolina Poddębniak-Strama, Magdalena Modzelewska, et al.
Cancer Immunology, Immunotherapy : CII|May 4, 2021
Human hydatid cyst fluid-induced therapeutic anti-cancer immune responses via NK1.1+ cell activation in miceEdgardo Berriel, Teresa Freire, Carolina Chiale, et al.
Pageof 651